You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

programmed death 1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Soluble Programmed Death-1 in Predicting Progression of

Recruiting
  • Nontuberculous Mycobacterial Lung Disease
    • Taipei, Taiwan
      National Taiwan University Hospital
    Jan 18, 2023

    NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • Tumor treating fields（EFE-P100）
    • Docetaxel injection
    • Shanghai, China
      Shanghai Pulmonary Hospital
    Dec 21, 2022

    Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

    Not yet recruiting
    • Acute Lymphoblastic Leukemia in Pediatric
    • flow cytometric immunophynotyping
    • Sohag, Egypt
      Sohag University Hospital
    Jun 19, 2022

    Soluble Programmed Death 1 isDiagnostic Biomarker of ILD in

    Not yet recruiting
    • Rheumatoid Arthritis
    • soluble programmed death 1biomarker
    • (no location specified)
    Jan 11, 2022

    Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)

    Active, not recruiting
    • Metastatic Nonsmall Cell Lung Cancer
    • Non Small Cell Lung Cancer
    • Stereotactic Body Radiotherapy
    • Philadelphia, Pennsylvania
      Philadelphia CyberKnife
    Mar 15, 2022

    NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +4 more
    • MK-2870
    • +2 more
    • (no location specified)
    Sep 15, 2023

    NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Wuhan, Hubei, China
      Qian Chu
    Aug 18, 2023

    Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal

    Not yet recruiting
    • Nasopharyngeal and Hypopharyngeal Carcinoma
    • immunohistochemical
    • Sohag, Egypt
      Sohag University Hospital
    Oct 23, 2022

    Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

    Recruiting
    • Peripheral T-Cell Lymphoma, Not Otherwise Specified
    • Angioimmunoblastic T-cell Lymphoma
    • Changchun, Jilin, China
      The First Bethune Hospital of Jilin University
    Apr 7, 2023

    Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in

    Recruiting
    • Malignant Pleural Mesothelioma, Advanced
    • Oncolytic Adenovirus H101
    • Programmed death receptor-1 inhibitor
    • Tianjin, Tianjin, China
      Tianjin Medical Unversity Second Hospital
    Sep 2, 2023

    Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

    Recruiting
    • Oral Squamous Cell Carcinoma
    • +3 more
    • Toripalimab (anti-programmed death-1 inhibitor)
    • +4 more
    • Shanghai, Shanghai, China
      Ninth People's Hospital, Shanghai Jiao Tong University School of
    Oct 8, 2022

    Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Chuo-ku, Tokyo, Japan
      National Cancer Center Hospital ( Site 3700)
    Jan 31, 2023

    PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

    Recruiting
    • Immune Checkpoint Inhibitors
    • +9 more
    • Radiotherapy for targeted lesions and PD-1 antibody
    • Beijing, Beijing, China
      Lei Li
    Apr 1, 2022

    PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
    • Monza, Italy
      ASST-Monza Ospedale San Gerardo
    Jun 9, 2022

    Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

    Recruiting
    • Breast Cancer
    • +2 more
    • Observational Study
    • Lucknow, Uttar Pradesh, India
      Sanjay Gandhi Postgraduate Institute of Medical Sciences
    Feb 11, 2022

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

    Completed
    • Colorectal Cancer
    • Fruquintinib combined with anti-PD-1 antibodies
    • ChangSha, Hunan, China
      Hunan Cancer Hospital
    Aug 27, 2023

    Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

    Enrolling by invitation
    • Hepatocellular Carcinoma Non-resectable
    • +3 more
    • lenvatinib + sindilimab/carrelizumab
    • TACE
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    May 23, 2022

    Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • regorafenib plus anti-PD-1 antibodies
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 4, 2023

    Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Peking, China
      Peking Union Medical College Hospital
    Nov 16, 2023

    Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

    Recruiting
    • Locally Advanced Cervical Cancer
    • Villejuif, Val De Marne, France
      Gustave Roussy
    Feb 15, 2022

    Multiple Myeloma Trial in Belgium, Israel, Spain (Daratumumab, JNJ-63723283)

    Completed
    Has Results
    • Multiple Myeloma
    • Antwerpen, Belgium
    • +12 more
    Dec 1, 2022

    Programmed Cell Death 1 Trial in Assiut (Thoracic Paravertebral block)

    Recruiting
    • Programmed Cell Death 1
    • Thoracic Paravertebral block
    • Assiut, Egypt
      South Egypt Cancer Institute
    Dec 5, 2020

    Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

    Completed
    • Recurrent/Metastatic Gastric Cancer
    • Nivolumab, Paclitaxel
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Sep 9, 2022

    Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma Trial in New York (Nivolumab, Atezolizumab, Radiation &

    Terminated
    Has Results
    • Metastatic Renal Cell Carcinoma
    • Metastatic Urothelial Carcinoma
    • New York, New York
      Weill Cornell Medicine - New York Presbyterian Hospital
    Aug 26, 2021